Mr. Jacob Thaysen, Ph.D. serves as Chief Executive Officer at Illumina, Inc. since September 25, 2023 and serves as its Director since September 2023. Mr. Thaysen joined the Illumina, Inc. in September 202...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jacob Thaysen	CEO & Director	less than a year	US$4.69m	0.0046% $ 953.5k
Carissa Rollins	Chief Information Officer	2.5yrs	US$2.93m	0.0011% $ 221.8k
Charles Dadswell	Senior VP & General Counsel	11.4yrs	US$4.10m	0.0044% $ 918.3k
Stephanie Campos	President	no data	데이터 없음	데이터 없음
Ankur Dhingra	Chief Financial Officer	no data	데이터 없음	데이터 없음
Kevin Pegels	Chief of Global Operations	2.8yrs	데이터 없음	0.011% $ 2.2m
Scott Ericksen	VP & Chief Accounting Officer	1.9yrs	데이터 없음	0.0067% $ 1.4m
Steven Barnard	Chief Technology Officer	1.1yrs	데이터 없음	0.017% $ 3.6m
Sallilyn Schwartz	Vice President of Investor Relations	3.7yrs	데이터 없음	데이터 없음
Jakob Wedel	Chief Strategy & Corporate Development Officer and CEO Chief of Staff	less than a year	데이터 없음	0.0044% $ 912.0k
Pat Leckman	Senior VP & Chief People Officer	less than a year	데이터 없음	0.0055% $ 1.1m
Nicole Berry	Head of Region-Americas	no data	데이터 없음	데이터 없음

1.9yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: ILMN 의 관리팀은 경험 (평균 재직 기간 1.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jacob Thaysen	CEO & Director	less than a year	US$4.69m	0.0046% $ 953.5k
Caroline Dorsa	Independent Director	7.7yrs	US$408.88k	0.0062% $ 1.3m
Susan Siegel	Independent Director	5.6yrs	US$398.58k	0.0050% $ 1.0m
Stephen MacMillan	Independent Chairman of the Board	1.3yrs	US$388.22k	0.00095% $ 196.9k
Philip Schiller	Independent Director	8.2yrs	US$395.10k	0.0086% $ 1.8m
Robert Epstein	Independent Director	11.8yrs	US$405.10k	0.0098% $ 2.0m
Gary Guthart	Independent Director	6.8yrs	US$404.29k	0.0063% $ 1.3m
Scott Ullem	Independent Director	1.3yrs	US$345.03k	0.0012% $ 244.6k
Frances Arnold	Independent Director	8.7yrs	US$400.10k	0.0092% $ 1.9m
Leslie Biesecker	Member of Ethics Advisory Board	no data	데이터 없음	데이터 없음
Scott Gottlieb	Independent Director	4.6yrs	US$391.37k	0.0035% $ 725.5k
Clement Adebamowo	Member of Ethics Advisory Board	no data	데이터 없음	데이터 없음

6.2yrs

평균 재임 기간

61.5yo

평균 연령

경험이 풍부한 이사회: ILMN 의 이사회는 경험(평균 재직 기간 5.9 년)으로 간주됩니다.

Illumina 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Illumina, Inc. Appoints Anna Richo to its Board of Directors

Illumina, Inc. Announces Chief Financial Officer Changes

CEO & Director recently bought US$992k worth of stock

Illumina, Ventures Announces Appointment of Mara Aspinall, MBA as Partner of Investment Team

Illumina, Inc. Announces Chief Executive Officer Changes

Illumina, Inc. Announces CEO Changes

Recent updates

European Court of Justice Rules in Favor of Illumina, Inc. in Relation to Relation to the European Commission's Acquisition of GRAIL

Illumina, Inc. Announces Food and Drug Administration Approval for Its Cancer Biomarker Test with Two Companion Diagnostics to Rapidly Match Patients to Targeted Therapies

Illumina Sees The Light: GRAIL Is Gone, Focus Restored (Rating Upgrade)

Consensus EPS estimates upgraded to US$9.60 loss

Now 23% overvalued after recent price rise

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Illumina, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2024

Illumina Launches New Oncology Menu for NovaSeq X Series Customers

Consensus EPS estimates fall from profit to US$1.71 loss

Illumina: Strengthening Competitive Position, Relevance And A Very Compelling Valuation

Illumina, Inc. (NasdaqGS:ILMN) acquired Fluent BioSciences Inc.

Illumina, Inc. (NasdaqGS:ILMN) acquired Fluent BioSciences Inc.

Illumina, Inc.'s (NASDAQ:ILMN) Share Price Could Signal Some Risk

Illumina: Marriage Made In Hell Is (Finally) Over - Assessing Impact Of GRAIL Spin-Out

Consensus EPS estimates upgraded to US$0.93 loss

Illumina, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Illumina, Inc.(NasdaqGS:ILMN) dropped from S&P 500 Value

Now 24% overvalued

Illumina Launches Latest Chemistry Across Most Popular Mid-Throughput Sequencers, Enabling Higher Quality and Greater Speed for Customers at Lower Cost

Should You Investigate Illumina, Inc. (NASDAQ:ILMN) At US$106?

Illumina, Inc. Appoints Anna Richo to its Board of Directors

Now 22% overvalued

Illumina: Expect A Slow Rebound

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Illumina, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Calculating The Fair Value Of Illumina, Inc. (NASDAQ:ILMN)

Consensus EPS estimates fall by 25%

Illumina, Inc. Announces Chief Financial Officer Changes

Illumina, Inc. to Report Q1, 2024 Results on May 02, 2024

Consensus EPS estimates upgraded to US$0.56 loss

Revenues Not Telling The Story For Illumina, Inc. (NASDAQ:ILMN)

CEO & Director recently bought US$992k worth of stock

Illumina: Stagnant Revenues And Shrinking Margins Amidst Rising Competition

Consensus EPS estimates fall by 64%

Consensus EPS estimates upgraded to US$0.41 loss, revenue downgraded

Full year 2023 earnings: EPS misses analyst expectations

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Illumina: Volatility Galore, But Not Much Prospect Of Progress In 2024

Illumina, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Pomerantz LLP Files a Class Action Lawsuit Against Illumina, Inc

Investors Appear Satisfied With Illumina, Inc.'s (NASDAQ:ILMN) Prospects As Shares Rocket 40%

Carl C. Icahn Releases Open Letter to Stockholders of Illumina, Inc

Now 20% undervalued after recent price drop

Hagens Berman Encourages Illumina Investors with Losses to Contact Firm’s Attorneys

Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued?

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Illumina, Inc

Price target decreased by 15% to US$168

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Carl Icahn Accuses Board and Ex-CEO of Illumina Inc

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Carl Icahn Sues Illumina Inc’s Board for Violating Fiduciary Duties

Price target decreased by 9.4% to US$203

EU Orders Illumina to Sell Cancer Testing Firm Grail

Illumina, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Is There An Opportunity With Illumina, Inc.'s (NASDAQ:ILMN) 40% Undervaluation?

Illumina, Ventures Announces Appointment of Mara Aspinall, MBA as Partner of Investment Team

Illumina, Inc. Announces Chief Executive Officer Changes

At US$167, Is Illumina, Inc. (NASDAQ:ILMN) Worth Looking At Closely?

Price target decreased by 7.0% to US$224

Second quarter 2023 earnings: EPS misses analyst expectations

Illumina, Inc. Provides Consolidated Earnings Guidance for the Year 2023

Guardant Resolves Pending Litigation with Illumina and Enters into New Agreement to Advance Long-Term Commercial Partnership and Cancer Research

Illumina, Inc. to Report Q2, 2023 Results on Aug 09, 2023

The Big Trends: New Frontiers in Healthcare

Illumina DRAGEN™ 4.2 Delivers Most Accurate and Comprehensive Coverage of the Genome, Powering Greater Applications and Discovery

Estimating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) Is Carrying A Fair Bit Of Debt

Illumina, Inc. Announces CEO Changes